New Delhi, August 6, 2026 (Yes Punjab News)
The Centre has introduced stricter provisions under the Drugs Rules, 1945, allowing licensing authorities to debar companies and applicants that submit fake or fabricated data while seeking regulatory approvals for drugs.
The Ministry of Health and Family Welfare (MoHFW) said the amendments aim to enhance transparency, accountability and integrity in India’s drug approval system by ensuring that applications are supported by genuine and scientifically valid information.
Under the revised rules, applicants found submitting fabricated, false or misleading data may face rejection of their applications, cancellation of existing licences and restrictions on filing fresh applications before the concerned regulatory authority for a specified period.
The government said the action will be taken only after following due process, including the issuance of a show-cause notice. The amended framework also provides a mechanism for appeal against such decisions.
The ministry highlighted that scientific data submitted by applicants plays a crucial role in assessing the quality, safety and efficacy of medicines before approval.
“Submission of fake or fabricated data compromises the integrity of the regulatory process, casts aspersions over the quality of drugs and may pose serious risks to public health,” the ministry said.
The Centre said the new provisions are intended to discourage malpractice, improve compliance among drug manufacturers and distributors, and strengthen safeguards against regulatory violations.
The amendments are part of wider reforms aimed at strengthening India’s pharmaceutical regulatory framework in line with global standards, the ministry added.
The government said the measures will help ensure that drug approvals are based on reliable evidence while promoting ethical practices and greater accountability across the pharmaceutical sector.
FOLLOW NOW
